AC Immune SA·4

Jun 15, 6:31 AM ET

June Carl Howard 4

Research Summary

AI-generated summary

Updated

AC Immune (ACIU) Director June Carl Howard Receives Award

What Happened
June Carl Howard, a director of AC Immune SA (ACIU), was granted equity awards on June 11, 2026: 16,568 restricted share units (RSUs) and share options covering 38,889 underlying shares. Both grants were reported at $0 (standard for awards/derivative grants) — these are compensation awards, not purchases or sales.

Key Details

  • Transaction date: June 11, 2026; Report filed June 15, 2026 (Form 4 accession 0001651625-26-000008).
  • Grants reported: 16,568 RSUs (footnote F1) and options for 38,889 shares (footnote F3). Reported acquisition price: $0. Total cash value at grant not stated in the filing.
  • Vesting: The share options “will fully vest on June 10, 2027” (F3). RSUs typically convert to shares upon vesting (per plan rules).
  • Holdings note: Footnote F2 indicates there are 66,556 common shares underlying outstanding RSUs included in the reporting person’s holdings.
  • Nature of transaction: Code A — award/grant (not an open-market buy or sale). No indication these options were exercised or shares sold.

Context
RSUs and option grants are a common form of director compensation; they do not represent immediate cash proceeds or sales. The options are a derivative grant that will only convert to shares if and when vested and exercised; they are scheduled to fully vest in one year. This filing reports the grant of awards rather than an executed purchase or sale, so it signals compensation allocation rather than an immediate insider market view.